Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity

Xiao Hong Bao, Munenori Takaoka, Hui Fang Hao, Zhi Gang Wang, Takuya Fukazawa, Tomoki Yamatsuji, Kazufumi Sakurama, Dong Sheng Sun, Takeshi Nagasaka, Toshiyoshi Fujiwara, Yoshio Naomoto

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Aim: To assess the effects of a novel type 1 insulin-like growth factor receptor (IGF-1R) inhibitor, NVP-AEW541, on cell proliferation and signal transduction of esophageal cancer. Materials and Methods: Cell proliferation assay and western blot were conducted to assess the antitumor effects of NVP-AEW541. Genetic modification of RAS by expression vector was applied for overexpression of mutant RAS. Results: More than 2 μmol/l of NVP-AEW541 was required to effectively inhibit the proliferation of esophageal cancer. NVP-AEW541 potently blocked the activation of IGF-1R and protein kinase B (PKB, also known as AKT), but not of mitogen-activated protein kinase kinase (MEK) and extracellular-signal-regulated kinases (ERK). Active RAS was not reduced by NVP-AEW541 in esophageal cancer cells TE-1, suggesting that insensitivity of esophageal cancer to NVP-AEW541 is due to the maintained RAS-MAPK activity, which did not arise from RAS mutation. Moreover, the transduction of mutant RAS reduced the sensitivity of TE-1 cells to NVP-AEW541. Conclusion: Stimulation of RAS-MAPK pathway is associated with resistance to NVP-AEW541 in esophageal cancer. Combining NVP-AEW541 with inhibitors/ antibodies against RAS-MAPK signaling molecules might be more effective for use against esophageal cancer.

Original languageEnglish
Pages (from-to)2827-2834
Number of pages8
JournalAnticancer research
Issue number7
Publication statusPublished - Jul 2012


  • Esophageal cancer
  • IGF-1R
  • NVP-AEW541
  • Ras-MAPK

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity'. Together they form a unique fingerprint.

Cite this